Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA
The pharmaceutical provisions included in the negotiated text of the U.S.-Mexico-Canada Agreement will do many things. But creating a market for biologics in Mexico is not one of them. Why? Because pharmaceutical companies have been selling original biologics in Mexico since before 2001.
AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track
Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.
The conference legal track:
The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions
In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.
American Patients Must Tell Congress to Fix the USMCA to Lower Drug Prices!
Highlights from the NAFTA 2.0 Congressional Briefing: The May 10 Amendments
On May 10, 2019, the Association for Accessible Medicines (AAM) hosted a briefing for congressional staff and other stakeholders on the twelfth anniversary of the May 10 Agreement, the bipartisan agreement to reopen the Colombia, Panama, Peru and South Korea trade agreements to address labor, environment and access to medicines issues.
Anniversary of the May 10 Trade Amendments
Together We Can Fix the USMCA
In 2007, a divided government compromised and agreed to advance America’s trade priorities. With bipartisan consensus to lower prescription drug costs, will the current political dynamic allow a similar deal?
The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It
The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars.
The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake.
NAFTA 2.0: Obstacles to More Affordable Meds
Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients. Learn more at: http://bit.ly/NAFTA-Obstacles-blog